metaLead is pioneering the development of novel drugs to treat metal-related diseases such as Wilson disease and lead poisoning. Our platform technology is based on a class of short peptides designed to tightly and selectively bind to metal ions of interest and expel them effectively and safely.
metaLead is currently focusing on Wilson disease, a rare genetic disorder causing the accumulation of copper in the liver and the brain in toxic amounts.
metaLead's drug peptides are superior to the standards of care in these disease areas thanks to unique characteristics that enable complete control of their biochemical features and mechanism of action.
News
Milestones/News
